Podcasts about pathology and lab medicine

Host: Brian P. McDonough, MD, FAAFP Guest: Marie Wood, MD Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate scientific rigor and clinical utility. Still, challenges remain, including false positives and integration with standard screening protocols. Joining Dr. Brian McDonough to explore the rationale for using a multi-biomarker approach to MCED testing is Dr. Marie Wood, Professor of Medicine at the University of Colorado School of Medicine and Medical Director of the Hereditary Cancer Program at the CU Cancer Center.

Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there's an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection. Reference: Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-recommendations-and-key-takeaways/36186/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-evidence-to-clinical-practice/36183/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-menin-directed-aml-therapy/36184/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-recommended-targeted-therapies-into-rr-aml-management/36181/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/molecular-profiling-as-a-cornerstone-of-precision-aml-therapy/36178/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/molecular-profiling-as-a-cornerstone-of-precision-aml-therapy/36178/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-recommended-targeted-therapies-into-rr-aml-management/36181/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-evidence-to-clinical-practice/36183/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-menin-directed-aml-therapy/36184/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/stratifying-risk-to-guide-therapy-in-rr-aml/36177/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-recommendations-and-key-takeaways/36186/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/stratifying-risk-to-guide-therapy-in-rr-aml/36177/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

Guest: Fernando López-Ríos, MD, PhD Guest: Christian Rolfo, MD, PhD Guest: Charlie Gourley, MD, PhD In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers. Topics of conversation include the following: An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results Targeting HER2 in lung cancer: where does IHC testing fit in? Ovarian cancer: challenges and considerations for HER2 IHC testing Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer. The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/is-it-nonresponsiveprogressive-ism/32714/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-treatment-of-systemic-mastocytosis-with-an-associated-hematologic-neoplasm/32715/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/is-it-nonresponsiveprogressive-ism/32714/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-treatment-of-systemic-mastocytosis-with-an-associated-hematologic-neoplasm/32715/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/accurate-diagnosis-and-management-of-hereditary-alpha-tryptasemia/32716/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/accurate-diagnosis-and-management-of-hereditary-alpha-tryptasemia/32716/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease. FA-11319389 12/24

Guest: Donald Kohan, MD, PhD Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City. References: Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143 Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023 Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321 Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301 Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670 FA-11319389 12/24

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-with-potentially-guideline-changing-implications-in-cllsll-and-mcl/32287/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-with-potentially-guideline-changing-implications-in-cllsll-and-mcl/32287/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-genitourinary-malignancies/29202/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-immunotherapy-combination-strategies-in-genitourinary-malignancies/29201/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-targeted-therapy-combination-strategies-in-genitourinary-malignancies/29200/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-recommendations-into-the-frontline-care-of-a-patient-with-mcrpc-who-is-naive-to-both-docetaxel-and-novel-hormone-therapy/29197/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-intensification-with-parp-inhibitor-combinations-in-patients-with-metastatic-castration-resistant-prostate-cancer/29196/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-frontline-immunotherapy-based-combination-regimens-in-metastatic-urothelial-cancer/29193/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Grady, MD While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Grady, MD While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.